By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French molecular diagnostics company IntegraGen has been awarded a €1.6 million ($2.4 million) interest-free loan from the French government to develop cancer biomarker tools, the company said Wednesday.

IntegraGen will use the loan from OSEO (the French state innovation agency) to partner with the French National Institute of Health and Medical Research (INSERM) to develop biomarker panels for personalized medicine and management of liver and colon cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.